Ens­pryng Relapse Reduction

Ens­pryng’s Phase III METEOROID trial for myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD) reached its primary endpoint, reducing the risk of a new relapse by 68 % versus placebo. At 48 weeks, 87 % of Ens­pryng recipients remained relapse‑free compared with 67 % on placebo. MRI data demonstrated a 79 % reduction in the annualized rate of active lesions, and 73 % fewer patients required rescue therapies such as steroids or plasma exchange. A non‑significant 17 % numerical drop in inpatient hospitalisations was also observed. Ens­pryng’s safety profile aligned with its established record in aquaporin‑4 seropositive neuromyelitis optica spectrum disorder, with no new signals and only mild injection‑related reactions and common viral infections noted.